Navigation Links
Ace Pelvic Stabilizer

ProductsAce Pelvic Stabilizer
Company DePuy Orthopaedics, Inc.
Item Ace Pelvic Stabilizer
Features 
  • Design and position of application allows unobstructed access to the abdomen and perineum for subsequent radiographic studies and surgical procedures
  • Can be affixed to the patient rapidly and easily as soon as the displaced pelvic ring disruption is identified
  • Reduces the external rotation component of a pelvic ring disruption so that one hemipelvis cannot move with respect to the other
  • Controls pelvic ring disruptions that have vertical displacement as well as external rotation
  • Description Massive hemorrhage associated with displaced pelvic fractures is one of the most serious emergencies faced by orthopaedic and trauma surgeons.

    Recognizing the difficulties when using the pneumatic antishock garment, external fixation, and internal fixation in these types of emergencies, the Pelvic Stabilizer has been developed as a method to provide emergent reduction and stabilization of pelvic ring disruption with associated hemorrhage.
    Info DePuy Orthopaedics, Inc.
    Customer Service: (800) 366-8143
    Web site: http://www.jnjgateway.com/home.jhtml?loc=USENG&page=viewContent&contentId=09008b9880772d01

    Related medicine products :

    1. Pelvic Fixator
    2. EBI Access Pelvic Fixator
    3. TC-100 Pelvic Fragment Set
    4. Pelvic Fragment Set
    5. Matta Pelvic Plating System
    6. Bledsoe Simple Pelvic Brace
    7. Duet EnCompass Pelvic Floor Diagnostic System
    8. Pelvicol Acellular Collagen Matrix (Continence)
    9. Pelvicol® Acellular Collagen Matrix
    10. Pelvic Washing for Cytology
    11. Duracon Total Stabilizer Revision System
    ...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
    ...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
    ...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
    ...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
    Medicine Products:
    (Date:12/2/2009)...te cancer patients who have a prostate-specific an...two years after external beam radiation therapy (E...nd cancer-related death, according to a study in t...f Radiation Oncology*Biology*Physics, the official...ology (ASTRO)., PSA levels in a prostate cancer ...
    (Date:12/2/2009)...DRIA, VA Constraint-induced movement therapy (CIM... for children with hemiplegic cerebral palsy, but ...atic review published in the November issue of Ph...he American Physical Therapy Association (APTA). T...and 2 systematic reviews, concluded that further r...
    (Date:12/2/2009)... AB First Aid has been a top name...on in 1980. With quality products, professional st...t aid supplies, AB First Aid has established itsel...mbulance care, and as a first aid supplies distrib...iness is about to enter into its next phase with t...
    (Date:12/2/2009)... National Race Series to increase...their families on the importance of early detectio...cember 2, 2009 -- Men, women, families, friends an...are invited to participate in the Rudolph Ramble 5...l PACE Race Series , which was launched by the P...
    (Date:12/2/2009)... A team of Kendall Hunt authors e... Year Award at the recent National Association for...Louis, November 5-7, 2009. , ... of Kendall Hunt authors earned the 2009 Gifted Ch...t National Association for Gifted Children’s...
    Breaking Medicine News(10 mins):Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2
    ... ABBOTT PARK, Ill., Jan. 21 Abbott ( NYSE: ...urth quarter ended Dec. 31, 2008. , , -- Dil..., were $1.06, reflecting 14.0 percent gro...e $0.98, up 27.3 percent., -- Worldwide sale...
    ... Company,s SAM1600 Family of Analog to Digital Con...ved Electronic Products, Product of The Year Award...ression Technology Named EDN Hot 100 Products of 2...ased to announce it has received top honors from i...
    ... For the first quarter of...ed rates on their Spanish translation services. On...marketing agencies in the United States, Auerbach ... -- Auerbach International Inc., one of the foremo...
    ... My1Stop.com, the eco fri...n Business Alliance® to provide customers with...tomers receive a 10% discount when using "My1...Stop.com, the eco friendly printing superstore, ha...
    ... In 2007, South Africa,s new Children,s Act came ...a host of rights relating to reproductive health, ...t policies allow individual schools to decide whet...h. , Juliana Han (Harvard Law School, Cambridge, ...
    ... , AIM and MedEmerg Combine to Form One of the ...anada, , , TORONTO, Jan. 20 /PRNewswire-FirstCall...ully integrated health care company, and Med-Emerg...viously disclosed all-stock merger transaction. Th...
    Other Medicine News:Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 2Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 3Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 4Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 5Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 6Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 7Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 8Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 9Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 10Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 11Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 12Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 13Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 14Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 15Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 16Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 17Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 18Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 19Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 20Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 21Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 22Health News:Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings 23Health News:Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines 2Health News:Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines 3Health News:Spanish On-Sale: Auerbach International Offers Discounted Rates for Spanish Translations 2Health News:Spanish On-Sale: Auerbach International Offers Discounted Rates for Spanish Translations 3Health News:My1Stop.com Partners with Green Business Alliance to Help Customers Go Green 2Health News:South African policy on adolescents' rights to access condoms is causing confusion 2Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 2Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 3Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 4Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 5Health News:AIM Health Group Inc. and Med-Emerg International Inc. Announce Completion of Previously Disclosed Merger Transaction 6
    (Date:12/2/2009)...sreal, December 2 Cardio...g developer of advanced,cardiovascular surgery tec...of Directors approved a one-for-three forward stoc...to Cardio Vascular Medical Device shareholders. ,...he estimated date the stock,split will be payable ...
    (Date:12/2/2009)...., Dec. 2 Roche (SIX: RO...ed States Food & Drug Administration (FDA) app...nucleic acid test, to screen source plasma in pool...test, called the cobas® TaqScreen MPX Test fo...e, in-vitro test for the simultaneous, direct dete...
    (Date:12/2/2009)...VER, N.J., Dec. 2 Novartis announc...presentation on Tasigna® (nilotinib) 200 mg c...onstrate the strength of the company,s hematology ..., The new data, at the 51st American Society of He...light the company,s current therapies and investig...
    Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Advance in bowel cancer test research 48298 1Discovery raises new doubts about dinosaur bird links 8763 1Discovery raises new doubts about dinosaur bird links 8763 2Discovery raises new doubts about dinosaur bird links 8763 3Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 1Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 2Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 3